View ValuationHK inno.N 향후 성장Future 기준 점검 1/6HK inno.N (는) 각각 연간 17.4% 및 7.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.8% 로 예상됩니다.핵심 정보17.4%이익 성장률17.50%EPS 성장률Pharmaceuticals 이익 성장21.2%매출 성장률7.4%향후 자기자본이익률5.80%애널리스트 커버리지Good마지막 업데이트08 Jun 2026최근 향후 성장 업데이트Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.모든 업데이트 보기Recent updates공시 • Apr 23HK inno.N Corporation to Report Q1, 2026 Results on Apr 28, 2026HK inno.N Corporation announced that they will report Q1, 2026 results on Apr 28, 2026Board Change • Apr 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Chairman of the Board Yeo-Won Son was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Declared Dividend • Mar 12Dividend of ₩410 announcedShareholders will receive a dividend of ₩410. Ex-date: 25th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.8%, which is lower than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 2.3% per year over the past 4 years and payments have been stable during that time.공시 • Mar 12HK inno.N Corporation, Annual General Meeting, Mar 26, 2026HK inno.N Corporation, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 178, osongsaengmyeong-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea공시 • Feb 11HK inno.N Corporation to Report Q4, 2025 Results on Feb 10, 2026HK inno.N Corporation announced that they will report Q4, 2025 results on Feb 10, 2026공시 • Jul 25HK inno.N Corporation to Report Q2, 2025 Results on Jul 30, 2025HK inno.N Corporation announced that they will report Q2, 2025 results on Jul 30, 2025New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공시 • Apr 22HK inno.N Corporation to Report Q1, 2025 Results on Apr 28, 2025HK inno.N Corporation announced that they will report Q1, 2025 results on Apr 28, 2025Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Executive Director Geun-Seok Song was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Mar 13HK inno.N Corporation, Annual General Meeting, Mar 26, 2025HK inno.N Corporation, Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 239, osongsaengmyeong 2-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea공시 • Mar 12598 Announces Annual DividendHK inno.N Corporation announced Annual dividend of KRW 350.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025.공시 • Oct 30HK inno.N Corporation to Report Q3, 2024 Results on Oct 30, 2024HK inno.N Corporation announced that they will report Q3, 2024 results on Oct 30, 2024Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.공시 • Mar 14HK inno.N Corporation, Annual General Meeting, Mar 28, 2024HK inno.N Corporation, Annual General Meeting, Mar 28, 2024, at 09:01 Korea Standard Time.Upcoming Dividend • Dec 20Upcoming dividend of ₩320 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%).공시 • Jul 26HK inno.N Corporation to Report Q2, 2023 Results on Aug 01, 2023HK inno.N Corporation announced that they will report Q2, 2023 results on Aug 01, 2023Board Change • Jun 30High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Chairman, CEO & President Dal-Won Kwak is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩320 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₩50,100, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Pharmaceuticals industry in South Korea.Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.이익 및 매출 성장 예측KOSDAQ:A195940 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,267,357124,134174,360206,263912/31/20271,206,413109,818157,960171,6801112/31/20261,118,47893,586139,460174,5221112/31/20251,063,64977,51886,160133,4201012/31/2024911,19363,73571,456112,9501312/31/2023827,22547,06558,60078,256109/30/2022839,62741,49114,55642,613N/A6/30/2022830,09534,8074,15430,706N/A3/31/2022763,16020,425-5,79711,201N/A12/31/2021769,78621,345-4,70126,796N/A9/30/2021743,84528,39118,59367,922N/A6/30/2021706,48232,0165,75083,515N/A3/31/2021652,47733,123-17,68067,594N/A12/31/2020598,44727,897-39,48354,106N/A9/30/2020559,66920,597-42,55136,523N/A6/30/2020550,29213,822-34,26032,044N/A3/31/2020546,46514,10520,65785,280N/A12/31/2019539,90813,21755,902103,074N/A9/30/2019526,28828,68341,16579,366N/A6/30/2019508,36422,21010,92237,602N/A3/31/2019499,10835,832-98117,548N/A12/31/2018490,70047,74311,37321,757N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A195940 의 연간 예상 수익 증가율(17.4%)이 saving rate(3.1%)보다 높습니다.수익 vs 시장: A195940 의 연간 수익(17.4%)이 KR 시장(33.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: A195940 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: A195940 의 수익(연간 7.4%)이 KR 시장(연간 16.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: A195940 의 수익(연간 7.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A195940의 자본 수익률은 3년 후 5.8%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/20 22:08종가2026/06/19 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스HK inno.N Corporation는 15명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Dae Woong YooBookook Securities Co. LtdJisoo LeeDAOL Investment & Securities Co., Ltd.Myung Sun LeeDB Financial Investment Co. Ltd.12명의 분석가 더 보기
Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.
Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.
Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.
Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.
Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.
공시 • Apr 23HK inno.N Corporation to Report Q1, 2026 Results on Apr 28, 2026HK inno.N Corporation announced that they will report Q1, 2026 results on Apr 28, 2026
Board Change • Apr 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Chairman of the Board Yeo-Won Son was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Declared Dividend • Mar 12Dividend of ₩410 announcedShareholders will receive a dividend of ₩410. Ex-date: 25th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.8%, which is lower than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 2.3% per year over the past 4 years and payments have been stable during that time.
공시 • Mar 12HK inno.N Corporation, Annual General Meeting, Mar 26, 2026HK inno.N Corporation, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 178, osongsaengmyeong-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
공시 • Feb 11HK inno.N Corporation to Report Q4, 2025 Results on Feb 10, 2026HK inno.N Corporation announced that they will report Q4, 2025 results on Feb 10, 2026
공시 • Jul 25HK inno.N Corporation to Report Q2, 2025 Results on Jul 30, 2025HK inno.N Corporation announced that they will report Q2, 2025 results on Jul 30, 2025
New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공시 • Apr 22HK inno.N Corporation to Report Q1, 2025 Results on Apr 28, 2025HK inno.N Corporation announced that they will report Q1, 2025 results on Apr 28, 2025
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Executive Director Geun-Seok Song was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Mar 13HK inno.N Corporation, Annual General Meeting, Mar 26, 2025HK inno.N Corporation, Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 239, osongsaengmyeong 2-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
공시 • Mar 12598 Announces Annual DividendHK inno.N Corporation announced Annual dividend of KRW 350.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025.
공시 • Oct 30HK inno.N Corporation to Report Q3, 2024 Results on Oct 30, 2024HK inno.N Corporation announced that they will report Q3, 2024 results on Oct 30, 2024
Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.
Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.
공시 • Mar 14HK inno.N Corporation, Annual General Meeting, Mar 28, 2024HK inno.N Corporation, Annual General Meeting, Mar 28, 2024, at 09:01 Korea Standard Time.
Upcoming Dividend • Dec 20Upcoming dividend of ₩320 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%).
공시 • Jul 26HK inno.N Corporation to Report Q2, 2023 Results on Aug 01, 2023HK inno.N Corporation announced that they will report Q2, 2023 results on Aug 01, 2023
Board Change • Jun 30High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Chairman, CEO & President Dal-Won Kwak is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩320 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).
Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₩50,100, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Pharmaceuticals industry in South Korea.
Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.